Characteristic	Overall, N = 956[1]	PAD-Group 1, N = 608[1]	PAD-Group 2, N = 348[1]	p-value[2]
Highest Statin dose				0.017
high	389 (41%)	230 (38%)	159 (46%)	
low/medium	567 (59%)	378 (62%)	189 (54%)	
Bezafibrat	3 (0.3%)	1 (0.2%)	2 (0.6%)	0.3
Fenofibrat	1 (0.1%)	1 (0.2%)	0 (0%)	>0.9
Gemfibrozil	0 (0%)	0 (0%)	0 (0%)	
Alirocumab	0 (0%)	0 (0%)	0 (0%)	
Ezetimib	28 (2.9%)	21 (3.5%)	7 (2.0%)	0.2
Treatment according to Guildeline 2016				0.001
aim not reached	599 (63%)	404 (66%)	195 (56%)	
aim reached	357 (37%)	204 (34%)	153 (44%)	

Characteristic	Overall, N = 956[1]	PAD-Group 1, N = 608[1]	PAD-Group 2, N = 348[1]	p-value[2]
Treatment according to Guildeline 2019				<0.001
aim not reached	760 (79%)	505 (83%)	255 (73%)	
aim reached	196 (21%)	103 (17%)	93 (27%)	
Treatment according to Guildeline 2016 in Patients with low intensity Statin				0.003
aim not reached	360 (66%)	256 (70%)	104 (57%)	
aim reached	189 (34%)	111 (30%)	78 (43%)	
Treatment according to Guildeline 2016 in Patients with high intensity Statin				0.2
aim not reached	229 (59%)	142 (62%)	87 (55%)	
aim reached	160 (41%)	88 (38%)	72 (45%)	

Characteristic	Overall, N = 956[1]	PAD-Group 1, N = 608[1]	PAD-Group 2, N = 348[1]	p-value[2]
Treatment according to Guildeline 2019 in Patients with low intensity Statin				<0.001
aim not reached	457 (83%)	320 (87%)	137 (75%)	
aim reached	92 (17%)	47 (13%)	45 (25%)	
Treatment according to Guildeline 2019 in Patients with high intensity Statin				0.12
aim not reached	290 (75%)	178 (77%)	112 (70%)	
aim reached	99 (25%)	52 (23%)	47 (30%)	

PAD-Group 1: PAD grade IIa and IIb

PAD-Group 2: III, IV, and diabetic foot syndrom

[1]n (%)

[2]Pearson's Chi-squared test; Fisher's exact test